CSF3 and myelodysplastic syndrome: Although the effective rate of YSNJF treatment is not significantly higher than that of granulocyte-colony stimulating factor (G-CSF) treatment (70.00% vs 59.1%, 23 MDS patients in each group, P > 0.05), YSNJF treated patients had a much lower serum concentration of sICAM-1 and HIF1α than those of G-CSF treatment [8].